Poseida Therapeutics, Inc. (PSTX)

$2.5

-0.08 (-3.10%)
Rating:
Recommendation:
-
Symbol PSTX
Price $2.5
Beta 0.000
Volume Avg. 0.25M
Market Cap 156.762M
Shares () -
52 Week Range 1.82-11.1
1y Target Est -
DCF Unlevered PSTX DCF ->
DCF Levered PSTX LDCF ->
ROE -97.92% Strong Sell
ROA -58.86% Strong Sell
Operating Margin -
Debt / Equity 139.29% Buy
P/E -
P/B 1.51 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PSTX news


Dr. Eric M. Ostertag
Healthcare
Biotechnology
NASDAQ Global Select

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.